title: Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
abstract: The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.
authors.affiliation: Department of Hematology, University Medical Center Groningen, The Netherlands. mmjbeckers@yahoo.com
authors.forename: Mariëlle M
authors.initials: MM
authors.lastname: Beckers
authors.forename: Gerwin
authors.initials: G
authors.lastname: Huls
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy* / Q000473:pathology; D000077269:Lenalidomide; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013792:Thalidomide; D000077269:Lenalidomide; D011241:Prednisone